Thursday, 19 November, 2026

3:02 AM

, Kuching, Sarawak

European Union approves new drug for pancreatic cancer

Facebook
X
WhatsApp
Telegram
Email
Online pharmacy

LET’S READ SUARA SARAWAK/ NEW SARAWAK TRIBUNE E-PAPER FOR FREE AS ​​EARLY AS 2 AM EVERY DAY. CLICK LINK

BRUSSELS, Belgium: The European Commission has approved a new drug for the treatment of pancreatic cancer, reported German news agency dpa. 

The drug daraxonrasib, sold under the brand name Rasonque, does not promise a cure but is meant to extend survival compared with chemotherapy. The drug can be used in adult patients who have previously received at least one type of cancer treatment, the Commission said in Brussels. 

The European Medicines Agency (EMA) had recommended approval in October.

The new drug is meant to slow the growth of tumour cells. It acts on a protein in cells that is altered in around 90 per cent of cases of pancreatic cancer and causes cancer cells to multiply uncontrollably.

In a study involving 500 patients with advanced pancreatic cancer, the drug was compared with chemotherapy for its effect on survival. Patients who received daraxonrasib lived on average for a further 12.4 months, compared with 6.7 months for those treated with chemotherapy.

Pancreatic cancer causes no symptoms, or only non-specific ones such as weight loss or pain in the upper abdomen or back, for a long time. The tumour is therefore often detected late, frequently only once it has already spread. 

This type of cancer is fatal within a short time for most of those affected. Only about one in 10 people is still alive five years after diagnosis, according to cancer registry data from the German government health agency, Robert Koch Institute (RKI). The disease usually occurs in people aged over 70. – BERNAMA-dpa

Related News